Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2TESM)

Drug Name

EPZ028862 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histone-lysine N-methyltransferase SMYD3 (SMYD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EPZ031686	DM8UKL0	Solid tumour/cancer	2A00-2F9Z	Preclinical	[2]
EPZ0330456	DMUKVYL	Colon cancer	2B90.Z	Preclinical	[1]
GSK2807	DMAZROV	Solid tumour/cancer	2A00-2F9Z	Preclinical	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone-lysine N-methyltransferase SMYD3 (SMYD3)	TTKLJYX	SMYD3_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
2	Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opin Ther Targets. 2017 Feb;21(2):145-157.
3	Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016 May 3;24(5):774-781.